Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Established Biologics Do Not Require Name Change, AbbVie Says

Executive Summary

Company objects to FDA's plans to retrospectively adopt suffix-based nomenclature for existing biologic products; says resulting confusion, logistical challenges and burdens outweigh FDA's 'not compelling' rationale about perceived inferiority of biosimilars due to different naming conventions.

Advertisement

Related Content

AbbVie Looks To White House For Relief From US FDA Naming Guidance

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057253

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel